Kari Wisinski
University of Wisconsin, Madison
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kari Wisinski as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:36 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07706179 · Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast CancerUniversity of Wisconsin, Madison · not yet recruiting · HR+/HER2+ Breast Cancer, Metastatic Breast Cancer · principal investigator
- Early Ph1NCT04174352 · FES Imaging to Optimize Tamoxifen for Metastatic Breast CancerUniversity of Wisconsin, Madison · recruiting · ERα+ Breast Cancer, ESR1 Gene Mutation · principal investigator
- Ph1/Ph2NCT03911973 · Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast CancersKari Wisinski · active not recruiting · TNBC - Triple-Negative Breast Cancer · principal investigator
- Ph2NCT03733119 · ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast CancerUniversity of Wisconsin, Madison · terminated · Triple Negative Breast Cancer · principal investigator
- Ph2NCT03301350 · Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast CancerUniversity of Wisconsin, Madison · completed · Breast Cancer, Triple Negative Breast Cancer · principal investigator
- Ph2NCT03186937 · A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast CancerUniversity of Wisconsin, Madison · terminated · Breast Cancer, Triple Negative Breast Cancer · principal investigator
- Ph1/Ph2NCT03090165 · Ribociclib and Bicalutamide in AR+ TNBCKari Wisinski · active not recruiting · Triple Negative Breast Cancer · principal investigator
- Ph1NCT02780401 · Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in RemissionUniversity of Washington · completed · HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes · principal investigator
- Ph1NCT01625156 · Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by SurgeryNational Cancer Institute (NCI) · completed · Adult Solid Neoplasm · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- National Clinical Trials Network Research at the University of WisconsinUG1CA233277 · NCI · UNIVERSITY OF WISCONSIN-MADISON · fiscal years 2022 to 2026 · $728,001 awarded in 2026Same name and institution; not confirmed by an ID
- Clinical Protocol and Data ManagementP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · fiscal years 2023 to 2025 · $676,114 awarded in 2025Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis (U01)U01CA062491 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI GLENN LIU · fiscal years 1994 to 2013Named on NCT01625156
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:36 UTC. The ranking covers the 200 most relevant of 22 PubMed records, and a shared surname and initials can bring in a namesake. All 22 on PubMed
- 201 citationsRCR 16.1
- A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.Clin Cancer Res · 201767 citationsRCR 2.0
- Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer.Oncologist · 201652 citationsRCR 1.8
- Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer.Clin Cancer Res · 201646 citationsRCR 1.3
- A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors.Clin Cancer Res · 202239 citationsRCR 2.4
- 22 citationsRCR 1.3
- Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study.Clin Breast Cancer · 201620 citationsRCR 0.7
- 18 citationsRCR 0.5
- A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.Invest New Drugs · 201718 citationsRCR 0.6
- A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782).Cancer Med · 202212 citationsRCR 0.8